Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Urinary Incontinence - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H2 2016', provides an overview of the Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence - The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects - The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Urinary Incontinence Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Urinary Incontinence Overview 8 Therapeutics Development 9 Pipeline Products for Urinary Incontinence - Overview 9 Pipeline Products for Urinary Incontinence - Comparative Analysis 10 Urinary Incontinence - Therapeutics under Development by Companies 11 Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes 12 Urinary Incontinence - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Urinary Incontinence - Products under Development by Companies 16 Urinary Incontinence - Products under Investigation by Universities/Institutes 17 Urinary Incontinence - Companies Involved in Therapeutics Development 18 Astellas Pharma Inc. 18 Celogos 19 Cook MyoSite Incorporated 20 FemmePharma Global Healthcare, Inc. 21 GTx, Inc. 22 Innovacell Biotechnologie AG 23 Ipsen S.A. 24 Outpost Medicine Limited 25 Taiho Pharmaceutical Co., Ltd. 26 Takeda Pharmaceutical Company Limited 27 TheraVida, Inc. 28 Urinary Incontinence - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 (mirabegron + solifenacin succinate) - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 abobotulinumtoxin A - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ASP-2205 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Cell Therapy for Urinary Incontinence - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 enobosarm - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Gtx-027 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 ICES-13 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 OP-233 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 oxybutynin chloride - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Prof-003 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 RCD-1 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 TAS-303 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 THVD-201 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 THVD-202 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Urinary Incontinence - Dormant Projects 66 Urinary Incontinence - Discontinued Products 69 Urinary Incontinence - Product Development Milestones 71 Featured News & Press Releases 71 Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting 71 Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting 71 Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence 72 Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence 72 May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 73 Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 74 Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 74 Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 75 Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients 75 Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 76 Aug 30, 2011: Innovacell passes a further milestone 76 May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 77 Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 78 Feb 22, 2011: Innovacell makes further progress on product development 78 Jun 28, 2010: Astellas and Teva reached a Settlement Agreement on VESIcare Patent Case 79 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
Number of Products under Development for Urinary Incontinence, H2 2016 9 Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Urinary Incontinence - Pipeline by Astellas Pharma Inc., H2 2016 18 Urinary Incontinence - Pipeline by Celogos, H2 2016 19 Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H2 2016 20 Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016 21 Urinary Incontinence - Pipeline by GTx, Inc., H2 2016 22 Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2016 23 Urinary Incontinence - Pipeline by Ipsen S.A., H2 2016 24 Urinary Incontinence - Pipeline by Outpost Medicine Limited, H2 2016 25 Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 26 Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 27 Urinary Incontinence - Pipeline by TheraVida, Inc., H2 2016 28 Assessment by Monotherapy Products, H2 2016 29 Assessment by Combination Products, H2 2016 30 Number of Products by Stage and Target, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 34 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Urinary Incontinence - Dormant Projects, H2 2016 66 Urinary Incontinence - Dormant Projects (Contd..1), H2 2016 67 Urinary Incontinence - Dormant Projects (Contd..2), H2 2016 68 Urinary Incontinence - Discontinued Products, H2 2016 69 Urinary Incontinence - Discontinued Products (Contd..1), H2 2016 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.